DDInter781 DDInter1828
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Fosinopril {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Photosensitivity reaction {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Fosinopril {u} (Compound) resembles {v} (Compound) Trandolapril
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Fosinopril {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Photosensitivity reaction {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Fosinopril {u} (Compound) resembles {v} (Compound) Trandolapril
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A2
SLC15A2 {u} (Gene) is bound by {v} (Compound) Quinapril
Quinapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Fosinopril {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Photosensitivity reaction {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Fosinopril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Tolbutamide (Compound)
Fosinopril (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolbutamide (Compound)
Fosinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Fosinopril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Tolbutamide (Compound)
Fosinopril (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Fosinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Fosinopril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Fosinopril (Compound) binds SLC15A2 (Gene) and SLC15A2 (Gene) is bound by Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Fosinopril (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)